Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
set to increase in 2024-2025 timeframe
INNOVATION
Key assets* with submission enabling readouts in 2024-2025
Pelacarsen
CVRR
Readout and submission in 2025
Iptacopan
Additional readouts/submissions
in 2025/2026+
lanalumab
1L and 2L ITP readouts in 2025
with submission in 2026
Additional hematology and
immunology indications 2026+
PluvictoⓇ
MHSPC
Readout and submission in 2024
Remibrutinib
CSU
Readout and submission in 2024
OAV-101
SMA IT
Readout in 2024; submission in 2025
ScemblixⓇ
1L CML-CP
Readout in 2024; submission in 2025
* Unprobabilized peak sales of all asset indications in late-stage development: > USD 1bn
> USD 2bn
> USD 3bn
12 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation